"Imipenem" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.
| Descriptor ID |
D015378
|
| MeSH Number(s) |
D02.065.589.099.124.300.500 D03.633.100.300.124.300.500
|
| Concept/Terms |
Imipenem- Imipenem
- N-Formimidoylthienamycin
- N Formimidoylthienamycin
- Imipemide
|
Below are MeSH descriptors whose meaning is more general than "Imipenem".
Below are MeSH descriptors whose meaning is more specific than "Imipenem".
This graph shows the total number of publications written about "Imipenem" by people in this website by year, and whether "Imipenem" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1998 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2018 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Imipenem" by people in Profiles.
-
A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia. J Antimicrob Chemother. 2024 Oct 01; 79(10):2543-2553.
-
Unveiling the structural features that regulate carbapenem deacylation in KPC-2 through QM/MM and interpretable machine learning. Phys Chem Chem Phys. 2023 Jan 04; 25(2):1349-1362.
-
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales. Clin Microbiol Infect. 2022 Nov; 28(11):1503.e1-1503.e3.
-
In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancer. J Glob Antimicrob Resist. 2022 06; 29:1-6.
-
KPC-2 ?-lactamase enables carbapenem antibiotic resistance through fast deacylation of the covalent intermediate. J Biol Chem. 2021 Jan-Jun; 296:100155.
-
Differential active site requirements for NDM-1 ?-lactamase hydrolysis of carbapenem versus penicillin and cephalosporin antibiotics. Nat Commun. 2018 10 30; 9(1):4524.
-
Molecular epidemiology of ESBL-producing Klebsiella pneumoniae isolates in intensive care units of a tertiary care hospital, North of Iran. Cell Mol Biol (Noisy-le-grand). 2018 May 30; 64(7):75-79.
-
[Characterization of class 1 and class 2 integron gene cassettes in Escherichia coli strains isolated from urine cultures: a multicenter study]. Mikrobiyol Bul. 2016 Apr; 50(2):175-85.
-
In vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012 Jul; 56(7):3753-7.
-
Novel modeling framework to guide design of optimal dosing strategies for ?-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May; 56(5):2237-40.